Dannae Brown

机构：ViiV Healthcare (Spain)

发表论文 16 篇 · 总被引 465 次 · h-index 8

代表论文

• Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial (2019 · The Lancet Infectious Diseases · 被引 199)
• Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial (2019 · Clinical Infectious Diseases · 被引 113)
• P032: Dolutegravir versus raltegravir in ARV-experienced INI-naïve HIV+ adults: 48-week subgroup analysis of Latin American subjects in the SAILING study (2015 · Journal of the International AIDS Society · 被引 40)
• Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial (2024 · The Lancet HIV · 被引 31)
• Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance (2018 · AIDS Research and Human Retroviruses · 被引 22)
• Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review (2018 · Antiviral Therapy · 被引 18)